Point72 Europe (London) LLP Intra Cellular Therapies, Inc. Transaction History
Point72 Europe (London) LLP
- $1.62 Billion
- Q4 2024
A detailed history of Point72 Europe (London) LLP transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Point72 Europe (London) LLP holds 38,961 shares of ITCI stock, worth $5.13 Million. This represents 0.2% of its overall portfolio holdings.
Number of Shares
38,961
Previous 19,385
100.99%
Holding current value
$5.13 Million
Previous $1.42 Million
129.64%
% of portfolio
0.2%
Previous 0.1%
Shares
3 transactions
Others Institutions Holding ITCI
# of Institutions
419Shares Held
88.8MCall Options Held
284KPut Options Held
105K-
Vanguard Group Inc Valley Forge, PA9.72MShares$1.28 Billion0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$832 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.13MShares$675 Million0.03% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.25MShares$428 Million1.36% of portfolio
-
Norges Bank Oslo, Q83.21MShares$423 Million0.04% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $12.4B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...